Settlements, Significant Study Results, and Product Launches Lead to Advancements in Patient Care - Research Report on GSK,

     Settlements, Significant Study Results, and Product Launches Lead to
Advancements in Patient Care - Research Report on GSK, Isis, Endo, Pacira, and
                                 Dr. Reddy's

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 25, 2013

NEW YORK, July 25, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting
GlaxoSmithKline plc (NYSE: GSK), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS),
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), Pacira Pharmaceuticals Inc.
(NASDAQ: PCRX), and Dr. Reddy's Laboratories Ltd. (NYSE: RDY). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

GlaxoSmithKline plc Research Report

On July 22, 2013, GlaxoSmithKline plc (GSK) and GlaxoSmithKline Consumer
Nigeria Plc. (GSK Nigeria) announced the withdrawal of the proposed
arrangement under which the Company was to increase its indirect ownership in
GSK Nigeria to 75%. GSK and GSK Nigeria believe that the suspension of the
scheme of arrangement is necessary to consider appropriate amendments to the
proposal for GSK to increase its indirect ownership in GSK Nigeria. The Full
Research Report on GlaxoSmithKline plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-07-23/GSK]

--

Isis Pharmaceuticals, Inc. Research Report

On July 22, 2013, Isis Pharmaceuticals, Inc. (Isis) announced data from Phase
2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides
on stable doses of fibrates. The study revealed that patients treated with
ISIS-APOCIII Rx reported reductions of up to 70% in apolipoprotein C-III
(apoC-III) and up to 64% in triglycerides. Isis further added that the treated
patients witnessed an increase of upto 52% in high density lipoprotein
cholesterol (the good cholesterol) and an up to 77% reduction in apoC-III
associated very low density lipoprotein particles. Richard Geary, Ph.D.,
Senior Vice President of Development at Isis stated, "We look forward to
sharing the results from our ongoing Phase 2 study evaluating ISIS-APOCIIIRx
as a monotherapy in patients with severely high triglycerides. In this study,
we hope to show that treatment with ISIS-APOCIIIRx in patients with severely
high triglycerides also produces significant effects on apoC-III,
triglycerides and HDL-C." The Full Research Report on Isis Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-23/ISIS]

--

Endo Pharmaceuticals Holdings Inc. Research Report

On July 22, 2013, Endo Health Solutions Inc. (Endo Health Solutions) announced
the appointment of Don DeGolyer as Chief Operating Officer, Pharmaceuticals
with effect from August 1, 2013. Rajiv De Silva, President and CEO of Endo
Health Solutions, stated, "Don is a uniquely qualified, seasoned leader with
nearly three decades of experience in the healthcare industry. Don has broad
experience in both branded and generic pharmaceuticals and I have tremendous
confidence in his ability to drive operational excellence and growth."
According to the Company, Mr. DeGolyer previously served as President and CEO
of Sandoz Inc., and spent 11 years at Johnson & Johnson in various roles
including President of Marketing and Sales. The Full Research Report on Endo
Pharmaceuticals Holdings Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-23/ENDP]

--

Pacira Pharmaceuticals Inc. Research Report

On July 18, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced results from
the second IMPROVE study which assesses postsurgical opioid use and health
economic outcomes between patients receiving EXPAREL as the foundation of an
opioid-sparing multimodal regimen, versus a standard opioid-based analgesic
regimen. Jorge E. Marcet, M.D., the study's Lead Author and Professor and
Division Director of colon and rectal surgery at Morsani College of Medicine,
University of South Florida, said, "In these patients, an opioid-sparing
multimodal regimen using EXPAREL was shown to significantly reduce opioid
intake, enable earlier discharge and lower the associated costs of care
compared to a standard opioid-based pain management strategy". Dave Stack,
President, CEO and Chairman of Pacira Pharmaceuticals, Inc. added, "The
IMPROVE studies, which demonstrate measurable advantages when using an
EXPAREL-based multimodal regimen compared to an opioid-based approach, may
prompt a shift towards an opioid-sparing pain management model." The Full
Research Report on Pacira Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-07-23/PCRX]

--

Dr. Reddy's Laboratories Ltd. Research Report

On July 12, 2013, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced that
it has launched its Decitabine for Injection (50 mg) in the U.S. market on
July 11, 2013, after the Company received approval from US Food & Drug
Administration (FDA). According to the Company, the new launched product is a
therapeutic equivalent generic version of Dacogen and is available as a single
dose vial. According to IMS Health, the Dacogen brand generated U.S sales of
approximately $260 Million MAT for the most recent twelve months ending in
July 2013. The Full Research Report on Dr. Reddy's Laboratories Ltd. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-23/RDY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.